Financings in Brief: InSite Vision
This article was originally published in The Gray Sheet
Executive Summary
InSite Vision: Raises $8 mil. through private placements, including $7 mil. in convertible preferred stock to a group of institutional investors led by Credit Suisse First Boston, and $1 mil. in common stock to ophthalmic product firm Bausch & Lomb. The financing boosts the firm's cash and cash equivalents to more than $11 mil. and will enable continued development of its genetic technology-based tools for diagnosis and prognosis of glaucoma, the firm states...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.